L. Kristin Newby

Biography

After receiving her medical degree from Indiana University, Newby completed a residency in internal medicine, a cardiology fellowship, and a master’s degree in Health Science at Duke University Medical Center. She is a Professor of Medicine in the Division of Cardiology, Co-Director of the Cardiac Care Unit, and focuses on optimizing the process and quality of care delivery to patients with acute and chronic coronary artery disease. Newby’s general research interests include risk stratification in patients with acute and chronic coronary artery disease, discovery and application of biomarkers in the diagnosis and treatment of cardiovascular disease, and heart disease in women. Her focus on the genomic contribution to the development of coronary artery disease has informed her position as co-investigator in several ongoing projects exploring the use of RNA expression profiling, proteomics, and metabolomics for coronary event risk stratification. At the DCRI, Newby has led clinical trials of new therapies and treatment strategies for acute coronary syndromes. She has been the principal investigator of multiple studies assessing the use of novel protein biomarkers to enhance risk stratification and guide treatment selection in cardiovascular disease, and is currently pursuing the application of genomics for this purpose. She has authored more than 200 peer-reviewed publications. A member of the Steering Committee for the Duke CATHGEN biorepository, Newby also serves as principal investigator of the MURDOCK cardiovascular disease project, Reclassifying the Risk for Acute Coronary Events, and is a co-principal investigator for the MURDOCK Study, which is creating a 50,000-patient community registry and biorepository in Cabarrus County and Kannapolis, North Carolina. After receiving her medical degree from Indiana University, Newby completed a residency in internal medicine, a cardiology fellowship, and a master’s degree in Health Science at Duke University Medical Center. She is a Professor of Medicine in the Division of Cardiology, Co-Director of the Cardiac Care Unit, and focuses on optimizing the process and quality of care delivery to patients with acute and chronic coronary artery disease. Newby’s general research interests include risk stratification in patients with acute and chronic coronary artery disease, discovery and application of biomarkers in the diagnosis and treatment of cardiovascular disease, and heart disease in women. Her focus on the genomic contribution to the development of coronary artery disease has informed her position as co-investigator in several ongoing projects exploring the use of RNA expression profiling, proteomics, and metabolomics for coronary event risk stratification. At the DCRI, Newby has led clinical trials of new therapies and treatment strategies for acute coronary syndromes. She has been the principal investigator of multiple studies assessing the use of novel protein biomarkers to enhance risk stratification and guide treatment selection in cardiovascular disease, and is currently pursuing the application of genomics for this purpose. She has authored more than 200 peer-reviewed publications. A member of the Steering Committee for the Duke CATHGEN biorepository, Newby also serves as principal investigator of the MURDOCK cardiovascular disease project, Reclassifying the Risk for Acute Coronary Events, and is a co-principal investigator for the MURDOCK Study, which is creating a 50,000-patient community registry and biorepository in Cabarrus County and Kannapolis, North Carolina.

Research Interest

Clinical investigation the process and treatment of acute and chronic coronary artery disease and systems issues for delivery of care to patients with these illnesses. Particular interests include management of patients with chest pain and unstable angina, evaluation of the use of biochemical markers other than CK-MB for diagnosis and risk stratification in these patients, issues related to coronary artery disease in women, and systems issues regarding optimizing the process of delivery of care to patients with acute and chronic coronary artery disease. Finally, I have a strong interest in defining the genetic contribution to development of coronary artery disease.